Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis

Table 1 Studies according to the study population baseline characteristics.

Characteristics of study populations
Study	Number ^a		Mean age	Line of treatment	Type of lymphoma	HIV status	HBV status
	Intervention	control
Aviles 2007a	102	102	69.2	untreated	aggressive	neg.	anti-HBc -
Aviles 2007b	98	98	59.7	refractory	aggressive	neg.	anti-HBc -
Aviles 2010	47	53	50.0	refractory	aggressive	neg.	anti-HBc -
Buske 2009	36	33	60.5	untreated	indolent	neg.*	NR
Coiffier 2002	202	197	69.0	untreated	aggressive#	neg.	HBsAg -
Eve 2009	78	78	63.5	untreated	indolent	neg.	anti-HBc -
Forstpointner 2004	66	62	62.5	refractory	indolent	neg.*	NR
Habermann 2006	267	279	69.5	untreated	aggressive	neg.	NR
Herold 2007	105	96	58.5	untreated	indolent	neg.	NR
Hiddemann 2005	223	205	55.5	untreated	indolent	neg.*	NR
Kaplan 2005	99	51	42.7	untreated	aggressive	pos.	NR
Lenz 2005	62	60	61.5	untreated	indolent	neg.*	NR
Marcus 2005	162	159	52.5	untreated	Indolent §	neg.	HBsAg -
Pfreundschuh 2008a	304	305	68.5	untreated	aggressive#	neg.	NR
Pfreundschuh 2008b	306	307	68.0	untreated	aggressive#	neg.	NR
Robak 2010	276	276	62.5	refractory	indolent	neg.	HBsAg-
van Oers 2006	234	231	54.5	refractory	indolent	neg.	NR

a) number of patients included either in the control and intervention arm; NR = not reported; § this includes 1.2% undefined lymphomas; # this includes 6 to 20% proportion of indolent or undefined; * HIV status not specified and presumed as negative.

ISSN: 1741-7015